TY - JOUR
T1 - Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection
AU - Degasperi, Elisabetta
AU - Caprioli, Flavio
AU - El Sherif, Omar
AU - Back, David
AU - Colombo, Massimo
AU - Aghemo, Alessio
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Introduction: Inflammatory bowel diseases (IBD) require long-term administration of immunomodulatory treatments to maintain disease remission. Due to the high worldwide prevalence of hepatitis B (HBV) or C (HCV) virus infections, presence of concurrent hepatitis can be a relevant clinical issue to manage when treating IBD. Areas covered: The paper summarizes epidemiological data about IBD and HBV/HCV infection and reviews current knowledge about the natural history of HBV and HCV in the IBD setting, concentrating on risk of hepatitis reactivation during immunosuppressive treatment. Most updated recommendations for management of HBV and HCV infections in IBD patients are discussed. Expert commentary: The development of new drugs for IBD with different molecular targets and the availability of potent and efficacious antiviral drugs for HBV and HCV will simplify management of hepatitis infection in IBD patients in the near future.
AB - Introduction: Inflammatory bowel diseases (IBD) require long-term administration of immunomodulatory treatments to maintain disease remission. Due to the high worldwide prevalence of hepatitis B (HBV) or C (HCV) virus infections, presence of concurrent hepatitis can be a relevant clinical issue to manage when treating IBD. Areas covered: The paper summarizes epidemiological data about IBD and HBV/HCV infection and reviews current knowledge about the natural history of HBV and HCV in the IBD setting, concentrating on risk of hepatitis reactivation during immunosuppressive treatment. Most updated recommendations for management of HBV and HCV infections in IBD patients are discussed. Expert commentary: The development of new drugs for IBD with different molecular targets and the availability of potent and efficacious antiviral drugs for HBV and HCV will simplify management of hepatitis infection in IBD patients in the near future.
KW - Anti-TNF
KW - HBV
KW - HCV
KW - immunosuppressive treatment
KW - inflammatory bowel diseases
KW - viral hepatitis
UR - http://www.scopus.com/inward/record.url?scp=84996549495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996549495&partnerID=8YFLogxK
U2 - 10.1080/17474124.2016.1246181
DO - 10.1080/17474124.2016.1246181
M3 - Review article
AN - SCOPUS:84996549495
VL - 10
SP - 1373
EP - 1383
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
IS - 12
ER -